An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss when given ...

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...

Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...

Amgen's experimental drug MariTide shows promise in maintaining weight loss and lowering blood sugar in diabetes patients.

Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...

The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with diet and exercise alone, others find that adding weight loss medications like ...

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate ...

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new tab ...

The MarketWatch News Department was not involved in the creation of this content. MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to 20% Average Weight Loss ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. The company faces significant patent expiries but aims to offset losses with ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug ...